Connect
MJA
MJA

Prevention of breast cancer

Ian N Olver
Med J Aust 2016; 205 (10): . || doi: 10.5694/mja16.01007
Published online: 21 November 2016

Summary

  • Modifiable lifestyle factors may reduce the risk of developing breast cancer. Obesity is associated particularly with post-menopausal breast cancer. Diet is important, and exercise equivalent to running for up to 8 hours each week reduces the risk of breast cancer, both in its own right and through reducing obesity.
  • Alcohol consumption may be responsible for 5.8% of breast cancers in Australia and it is recommended to reduce this to two standard drinks per day. Drinking alcohol and smoking increases the risk for breast cancer and, therefore, it is important to quit tobacco smoking.
  • Prolonged use of combined oestrogen and progesterone hormone replacement therapy and oral contraceptives may increase breast cancer risk and this must be factored into individual decisions about their use.
  • Ionising radiation, either from diagnostic or therapeutic radiation or through occupational exposure, is associated with a high incidence of breast cancer and exposure may be reduced in some cases.
  • Tamoxifen chemoprevention may reduce the incidence of oestrogen receptor positive cancer in 51% of women with high risk of breast cancer. Uncommon but serious side effects include thromboembolism and uterine cancer. Raloxifene, which can also reduce osteoporosis, can be used in post-menopausal women and is not associated with the development of uterine cancer.
  • Surgical prophylaxis with bilateral mastectomy and salpingo-oophorectomy can reduce the risk of breast cancer in patients carrying BRCA1 or BRCA2 mutations. For preventive treatments, mammographic screening can identify other women at high risk.


  • Sansom Institute for Health Research, University of South Australia, Adelaide, SA


Correspondence: ian.olver@unisa.edu.au

Competing interests:

No relevant disclosures.

  • 1. Australian Institute of Health and Welfare. Australian Cancer Incidence and Mortality (ACIM) books. Canberra: AIHW; 2014. http://www.aihw.gov.au/acim-books/ (accessed Aug 2016).
  • 2. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012; 13: 1141-1151.
  • 3. Colditz GA, Kaphingst KA, Hankinson SE, et al. Family history and risk of breast cancer: nurses’ health study. Breast Cancer Res Treat 2012; 133: 1097-1104.
  • 4. Taylor R, Boyages J. Absolute risk of breast cancer for Australian women with a family history. Aust N Z J Surg 2000; 70: 725-731.
  • 5. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1159-1169.
  • 6. Fu R, Harris EL, Helfand M, Nelson HD. Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach. Stat Med 2007; 26: 1775-1787.
  • 7. Lambertini M, Santoro L, Del Maestro L, et al. Reproductive behaviours and risk of developing breast cancer according to tumour subtype: a systematic review and meta-analysis of epidemiological studies. Cancer Treat Rev 2016; 29: 65-76.
  • 8. World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
  • 9. Kendall BJ, Wilson LF, Olsen CM, et al. Cancers in Australia in 2010 attributable to overweight and obesity. Aust NZ J Public Health 2015; 39: 452-457.
  • 10. Arnold M, Jiang L, Stefanick ML, et al. Duration of adulthood overweight, obesity and cancer risk in the Women’s Health Initiative: A longitudinal study from the United States. PLOS Med. 2016; doi:10.1371/journal.pmed.1002081.
  • 11. Vainio H, Bianchini F. IARC handbooks of cancer prevention. Weight control and physical activity. Volume 6. Lyon: International Agency for Research on Cancer; 2002. http://www.iarc.fr/en/publications/pdfs-online/prev/handbook6/Handbook6-0.pdf (accessed Aug 2016).
  • 12. Wu Y, Zhang D, Kang S. Physical activity and risk of breast cancer: a meta-analysis of prospective studies. Breast Cancer Res Treat 2013; 137: 869-882.
  • 13. Kyu HH, Bachman VF, Alexander LT, et al. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden Disease Study 2013. BMJ 2016; 354: i3857.
  • 14. McTiernan A, editor. Cancer prevention and management through exercise and weight control. Boca Raton: Taylor and Francis, 2006.
  • 15. World Cancer Research Fund, American Institute for Cancer Research. Continuous update project report. Food, nutrition, physical activity, and the prevention of breast cancer. Washington, DC: AICR; 2010.
  • 16. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Personal habits and indoor combustions. Volume 100 E. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012; 100(Pt E): 1-538.
  • 17. Ridolfo B, Stevenson C. The quantification of drug-caused mortality and morbidity in Australia, 1998 (AIHW Cat. No. PHE 29; Drug Statistics Series. Report No. 7). Canberra: Australian Institute of Health and Welfare; 2001. http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442459309 (accessed Aug 2016).
  • 18. National Health and Medical Research Council. Australian guidelines to reduce health risks for drinking alcohol. Canberra: Commonwealth of Australia; 2009.
  • 19. Pandeya N, Wilson LF, Webb PM, et al. Cancers in Australia in 2010 attributable to the consumption of alcohol. Aust NZ J Public Health 2015; 39: 408-413.
  • 20. Balbo S, Brooks PJ. Implications of acetaldehyde-derived DNA adducts for understanding alcohol-related carcinogenesis. Adv Exp Med Biol 2015; 815: 71-88.
  • 21. Narod SA. Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol 2011; 8: 669-676.
  • 22. Porch JV, Lee IM, Cook NR, et al. Estrogen-progestin replacement therapy and breast cancer risk: the Women’s Health Study (United States). Cancer Causes Control 2002; 13: 847-854.
  • 23. Reeves GK, Beral V, Green J, et al. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006; 7: 910-918.
  • 24. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
  • 25. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009; 170: 12-23.
  • 26. Renard F, Vankrunkelsven P, Van Eycken L, et al. Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. Ann Oncol 2009; 21: 2356-2360, 2010.
  • 27. Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women’s Health Initiative clinical trial and observational study. Am J Epidemiol 2008; 167: 1407-1415.
  • 28. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
  • 29. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, volume 100. Review of human carcinogens. Lyon, France: IARC; 2012.
  • 30. Gaudet MM, Gapstur SM, Sun J, et al. Active smoking and breast cancer risk: original cohort data and meta-analysis. J Natl Cancer Inst 2013; 105: 515-525.
  • 31. Luzhna L, Kovalchuk O. Mammary gland and radiation: knowns and unknowns. Cell Cycle 2016; 15: 1975-1976.
  • 32. Andrieu N, Easton DF, Chang-Claude J, et al. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ Group. J Clin Oncol 2006; 24: 3361-3366.
  • 33. United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR): Effects of ionizing radiation. In: UNSCEAR 2006 report to the General Assembly with scientific annexes. Vol 1. New York, NY: United Nations, 2008.
  • 34. Mohan AK, Hauptmann M, Freedman DM, et al. Cancer and other causes of mortality among radiologic technologists in the United States. Int J Cancer 2003; 103: 259-267.
  • 35. Doody MM, Freedman DM, Alexander BH, et al. Breast cancer incidence in US radiologic technologists. Cancer 2006; 106: 2707-2715.
  • 36. Slack R, Young C, Rushton L. British Occupational Cancer Burden Study Group: Occupational cancer in Britain. Female cancers: breast, cervix and ovary. Br J Cancer 2012; 107 Suppl 1: S27-S32.
  • 37. Lin X, Chen W, Wei F, et al. Night-shift work increases morbidity of breast cancer and all-cause mortality: a meta-analysis of 16 prospective cohort studies. Sleep Med 2015; 16: 1381-1387.
  • 38. Fenga C. Occupational exposure and risk of breast cancer. Biomed Rep 2016; 4: 282-292.
  • 39. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879-1886.
  • 40. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013; 381: 1827-1834.
  • 41. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015; 16: 67-75.
  • 42. Smith SG, Sestak I, Forster A, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol 2016; 27: 575-590.
  • 43. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014; 111: 1041-1048.
  • 44. Forbes JF, Sestak I, Howell A, et al. Anastraqzole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomized controlled trial. Lancet 2016; 387; 866-873.
  • 45. Bardia A, Keenen TE, Ebbert J, et al. Personalising aspirin use for targeted breast cancer chemoprevention in postmenopausal women. Mayo Clin Proc 2016; 91: 71-80.
  • 46. Cancer Research UK [website]. Breast cancer statistics. London: Cancer Research UK; 2010. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast (accessed Aug 2016).
  • 47. Gierach GL, Ichikawa L, Kerlikowske K, et al. Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst 2012; 104: 1218-1227.
  • 48. Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 2008; 124: 31-42.
  • 49. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-1333.
  • 50. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014; 371: 497-506.
  • 51. Maas P, Barrdahl M, Joshi AD, et al. Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States. JAMA Oncol 2016; doi:10.1001/jamaoncol.2016.1025 [Epub ahead of print].
  • 52. Domchek SM, Friebel TM, Singer CF, et al. Association of risk reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010; 3104: 967-975.
  • 53. Spillane AJ. What is new in the surgical management and prevention of breast cancer? Med J Aust 2016; 204: 311-314. <MJA full text>
  • 54. Yao K, Stewart AK, Winchester DJ, Winchester DP. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998e2007. Ann Surg Oncol 2010; 17: 2554-2562.
  • 55. Hai X, Friebel TM, Singer CF, et al. Use of risk reducing surgeries in a prospective cohort of 1499 BRCA1 and BRCA 2 mutation carriers. Breast Cancer Res and Treat 2014; 148: 397-406.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.